Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting

Trial Profile

Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Minocycline (Primary)
  • Indications Gram-negative infections
  • Focus Therapeutic Use
  • Sponsors Rempex Pharmaceuticals
  • Most Recent Events

    • 13 Nov 2017 Planned End Date changed from 17 Nov 2017 to 11 Dec 2017.
    • 13 Nov 2017 Planned primary completion date changed from 17 Nov 2017 to 11 Dec 2017.
    • 18 Sep 2017 Planned initiation date changed from 1 Jun 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top